ライフサイエンスコーパス: papillary

1 /oxyphilic carcinomas (4/4 patients) than in papillary (1/5) or follicular (0/6) tumors.

2 , 47 (36%) had incidental thyroid cancer (24 papillary, 11 malignant FNA, 5 oncocytic/Hurthle cell, 2

3 a 50% reduction in Sox2 leads to widespread papillary adenocarcinoma in the bronchioles.

4 Autopsy revealed papillary adenocarcinoma of the lung with numerous metas

5 Papillary adenocarcinoma was significantly more frequent

6 leads to widespread Sox2+, Sox9+, and CC10+ papillary adenocarcinomas throughout the bronchioles.

7 golipids, are important for maintaining high papillary ammonium concentration and increased urinary a

8 The mean ER of clear cell, papillary and chromophobe RCC were 188+/-49.7, 35+/-8.9,

9 corticomedullary phase; mean enhancement of papillary and chromophobe RCCs peaked in the nephrograph

10 The mean WR of clear cell, papillary and chromophobe RCCs were 28.6+/-6.8, 47.6+/-5

11 cy, and histologic fidelity, these models of papillary and clear cell RCC should be significant contr

12 e has been shown to improve the detection of papillary and flat bladder lesions in comparison to conv

13 TERT promoter mutations occur in both papillary and flat lesions, are the most frequent geneti

14 TERT promoter mutation was observed in both papillary and flat lesions, as well as in low- and high-

15 d the TERT promoter in 76 well-characterized papillary and flat noninvasive urothelial carcinomas, in

16 in anaplastic thyroid cancers compared with papillary and follicular subtypes (P < 0.0001).

17 storation of iodide uptake in RAI-refractory papillary and follicular thyroid cancer cell lines.

18 ly exclusive desmoplasia and inflammation in papillary and follicular thyroid cancers and the presenc

19 apoptosis and induction of migration in both papillary and follicular thyroid carcinoma cell lines.

20 Papillary and micropapillary adenocarcinomas and nodal m

21 cers, develops via two tracks referred to as papillary and nonpapillary that correspond to clinically

22 corresponding to the transition between the papillary and reticular dermis.

23 olved nests of basaloid cells present in the papillary and reticular dermis.

24 d the pilosebaceous unit but also within the papillary and reticular dermis.

25 CD8+ T cells were rather located in both the papillary and reticular layers of the LP.

26 d by histopathological type of cancer ("only papillary" and "excluding microcarcinomas").

27 noma), papillary (pRCC, also known as kidney papillary) and chromophobe (chRCC, also known as kidney

28 alignant masses (including 41 clear cell, 20 papillary, and seven chromophobe renal cell carcinomas [

29 on showed that 4 lesions (25%) had a cystic, papillary, and solid growth pattern with an in situ comp

30 e histologic subtyping with lepidic, acinar, papillary, and solid patterns; micropapillary is added a

31 t with luminal and basal subtypes, including papillary architecture and squamous differentiation.

32 t mesenchymal FGF10 controls the size of the papillary area, while overall patterning remains unchang

33 oped hydronephrosis, characterized by severe papillary atrophy and dilatation of the pelvicalyceal sy

34 sphincterotomy (PS) combined with endoscopic papillary balloon dilation (EPBD) for CBD stone removal

35 ated by endoscopic sphincterotomy/endoscopic papillary balloon dilation (EST/EPBD) with negative ERC

36 In total sample, GO was associated with papillary bleeding index (P=0.001) and concomitant use o

37 n CsA and Tcr groups, GO was associated with papillary bleeding index (P=0.029 and 0.033, respectivel

38 th [DMF-T] index); 2) gingival inflammation (papillary bleeding index [PBI]); and 3) periodontal stat

39 and concurrent and predictive validity with papillary bleeding index were assessed, as was treatment

40 imaging enabled clear visualization of fine papillary branches in serous BOT and allowed for charact

41 re reported for all participants, those with papillary cancer only, and women only.

42 In addition to well-differentiated papillary cancer, STRN-ALK was found with a higher preva

43 resenting with symptomatic exudative retinal papillary capillary hemangioma with or without associati

44 Solid papillary carcinoma with reverse polarity (SPCRP) is a r

45 re as follows: clear cell carcinomas (n=23), papillary carcinomas (n=6), and chromophobe carcinomas (

46 alphavbeta3-positive vessels in the group of papillary carcinomas whereas it correlated with integrin

47 nes, severe cystic pathology, and ultimately papillary carcinomas with hepatic metastases.

48 the cases were histologically classified as papillary carcinomas, with 2 of them exhibiting follicul

49 We enrolled patients with metastatic papillary, chromophobe, or unclassified non-clear cell r

50 Finally, we reveal that papillary craniopharyngioma (PCP), a benign human pituit

51 ns in BRAF (resulting in p.Val600Glu) in all papillary craniopharyngiomas (3/3, 100%).

52 notyping revealed BRAF p.Val600Glu in 95% of papillary craniopharyngiomas (36 of 39 tumors) and mutat

53 Adamantinomatous and papillary craniopharyngiomas harbor mutations that are m

54 multiple superficial microdisruptions in the papillary dermis and epidermis.

55 icroscopy studies showed marked edema of the papillary dermis with an inflammatory infiltrate consist

56 nse dermal nests, and nucleated cells within papillary dermis, were more frequently found in this sub

57 induction was found to spread into the upper papillary dermis, whereas S100A9 was shown to induce fib

58 the epidermis, although also evident in the papillary dermis.

59 tic of type II ECs, including focal areas of papillary differentiation, protruding cytoplasm into the

60 Intravascular papillary endothelial hyperplasia (IPEH), also known as

61 Radiologically, intravascular papillary endothelial hyperplasia could be misdiagnosed

62 ARID1A were seen in five of 14 patients with papillary features but not in other RCC variants.

63 Presence of papillary features were associated with benefit, includi

64 tion in patients with ncRCC characterized by papillary features.

65 tion proteins into detergent-skinned cardiac papillary fibres harvested from non-transgenic mice that

66 reconstituted into detergent-skinned cardiac papillary fibres harvested from transgenic mice that exp

67 pidermal Shh stimulates proliferation of the papillary fibroblast lineage, whereas TGF-beta2 controls

68 rate but with a reduction in Lrig1-positive papillary fibroblasts in wounds.

69 does not prevent Hh target gene induction in papillary fibroblasts.

70 Papillary fibroelastomas (PFE) are benign neoplasms with

71 The majority of patients had papillary growth as a major component (n = 14).

72 ges, including midfacial recession (MFR) and papillary height (PH) loss.

73 utcome after proton beam therapy for retinal papillary hemangioma is convincing, whereas functional o

74 Sloan Kettering Cancer Center risk group and papillary histology.

75 paces (confirmed by CLE), and basal cell and papillary hyperplasia developed without surface erosions

76 e ovarian surface epithelium but resulted in papillary hyperplasia when coupled with Pten inactivatio

77 t esophageal inflammation and basal cell and papillary hyperplasia without loss of surface cells.

78 ed were changes in epithelial basal cell and papillary hyperplasia, surface erosions, intercellular s

79 evaluated were plaque index, gingival index, papillary index (PPI) (0 = no papilla, 1 = less than hal

80 ccumulation of ammonium in the medullary and papillary interstitium.

81 ferentiated estrogen receptor alpha-positive papillary invasive cancers appeared in efatutazone-treat

82 s) were found in both the epithelium and the papillary layer of the Lamina propria (LP), whereas CD68

83 nalysis of 15 tumors showed that pure cystic/papillary lesions had a significantly greater percentage

84 developed sporadic, macroscopic, intraductal papillary lesions with histologic and molecular features

85 solution of OCT enables the detection of the papillary loops.

86 ial progenitor cells via field effects along papillary/luminal and nonpapillary/basal pathways.

87 new histopathologic subcategories of acinar, papillary, micropapillary, and solid predominant adenoca

88 ach histological component (lepidic, acinar, papillary, micropapillary, and solid) in 5% increments.

89 each histologic component (lepidic, acinar, papillary, micropapillary, and solid) was recorded.

90 RI revealed a pancreatic lesion: intraductal papillary mucinous neoplasia (14 patients, 35%) and panc

91 One patient had a synchronous intraductal papillary mucinous neoplasia and pancreatic ductal adeno

92 ductal adenocarcinoma and 2 for intraductal papillary mucinous neoplasia), while the remaining 35 ar

93 BACKGROUND & AIMS: Intraductal papillary mucinous neoplasias (IPMNs) are precancerous c

94 guidelines for the management of intraductal papillary mucinous neoplasm (IPMN) and mucinous cystic n

95 r management of branch duct (BD) intraductal papillary mucinous neoplasm (IPMN) espouse safety of obs

96 n pancreatic duct (MPD)-involved intraductal papillary mucinous neoplasm (IPMN) has been established

97 y of pancreatic branch-duct (BD) intraductal papillary mucinous neoplasm (IPMN) is infrequent and tha

98 epithelial neoplasia (PanIN) and intraductal papillary mucinous neoplasm (IPMN) precursor lesions.

99 Human intraductal papillary mucinous neoplasm (IPMN) specimens were analyz

100 eover, cystic lesions resembling intraductal papillary mucinous neoplasm (IPMN) were observed as earl

101 AC) and its preneoplastic lesion intraductal papillary mucinous neoplasm (IPMN), to find new microRNA

102 asive carcinoma in patients with intraductal papillary mucinous neoplasm (IPMN).

103 Intraductal papillary mucinous neoplasm (particularly the branch duc

104 Intraductal papillary mucinous neoplasm and pancreatic neuroendocrin

105 for mucinous cystic neoplasm and intraductal papillary mucinous neoplasm are superior to the original

106 urgery, only one patient with an intraductal papillary mucinous neoplasm had high-grade dysplasia.

107 for neuroendocrine tumors (35%), intraductal papillary mucinous neoplasms (33%), solid pseudopapillar

108 t the development of branch duct intraductal papillary mucinous neoplasms (BD-IPMNs).

109 le-center population of resected intraductal papillary mucinous neoplasms (IPMN) of the pancreas with

110 guidelines for the management of intraductal papillary mucinous neoplasms (IPMN) recommend surgical t

111 llowing resection for pancreatic intraductal papillary mucinous neoplasms (IPMN) using targeted next-

112 pseudocysts, 2 cysts/remnants, 4 intraductal papillary mucinous neoplasms (IPMN), 2 adenocarcinomas,

113 n about the origin of pancreatic intraductal papillary mucinous neoplasms (IPMN).

114 vating mutations are reported in intraductal papillary mucinous neoplasms (IPMNs) and in McCune-Albri

115 cystic PDAC precursors known as intraductal papillary mucinous neoplasms (IPMNs) and predictors of t

116 Intraductal papillary mucinous neoplasms (IPMNs) are the most freque

117 nes, the diagnostic criterion of intraductal papillary mucinous neoplasms (IPMNs) involving the main

118 dvances in radiographic imaging, Intraductal Papillary Mucinous Neoplasms (IPMNs) of the pancreas are

119 encountered in association with intraductal papillary mucinous neoplasms (IPMNs) of the pancreas.

120 3 node-negative R0 microinvasive intraductal papillary mucinous neoplasms (without recurrence at 27,

121 nically, mucinous cysts, such as intraductal papillary mucinous neoplasms and mucinous cystic neoplas

122 Intraductal papillary mucinous neoplasms are the most common pancrea

123 igh-risk lesions (ie, high-grade intraductal papillary mucinous neoplasms or grade 3 pancreatic intra

124 ed tumors (4/58, 6.9%) than non- intraductal papillary mucinous neoplasms PDAC (5/385, 1.3%) (P = .02

125 d dMMR in a larger proportion of intraductal papillary mucinous neoplasms-related tumors (4/58, 6.9%)

126 the management of patients with Intraductal Papillary Mucinous Neoplasms.

127 (32 [63%] male; mean age 61+/-15 years) with papillary muscle (n=18), fascicular (n=15), and mitral a

128 n=37; 38.1%), LV trabeculations (n=5; 5.2%), papillary muscle (n=3; 3.1%), and apical-septal bundle (

129 we sought to identify mitral valve (MV) and papillary muscle (PM) abnormalities that predisposed to

130 volume, tethering volume, bending angle, and papillary muscle angle were measured.

131 zing restrictive mitral annuloplasty (RA) or papillary muscle approximation with undersizing restrict

132 imension, left ventricular volume, and inter-papillary muscle distance were measured.

133 ntly change left ventricular volume or inter-papillary muscle distance.

134 sually caused by chordae tendinae rupture or papillary muscle dysfunction.

135 gle myosins in relaxed permeabilized porcine papillary muscle fibers indicated slightly differently o

136 RLC (RLC-PAGFP) exchanged into permeabilized papillary muscle fibers.

137 KI hearts exhibited atrial enlargement, papillary muscle hypertrophy, and fibrosis.

138 The prognostic significance of papillary muscle infarction (PapMI) on hard clinical out

139 m(2)), and lack of echocardiographic scar at papillary muscle insertion sites (all P<0.05) and, when

140 ctions of the outflow tract alternating with papillary muscle or fascicular origin.

141 from the outflow tract alternating with the papillary muscle or fascicular region (7 of 9 [78%] vs.

142 oci being mapped at either the anterolateral papillary muscle or posteromedial papillary muscles of t

143 Papillary muscle relocation restores the physiologic con

144 Papillary muscle retraction was combined with apical MI

145 s study sought to investigate the benefit of papillary muscle surgery on long-term clinical outcomes

146 Under cardiopulmonary bypass, the papillary muscle tips in 6 sheep were retracted apically

147 Papillary muscle VAs were distinguished electrocardiogra

148 Patients with papillary muscle VAs were older and had higher prevalenc

149 thm, the accuracy rates for the diagnosis of papillary muscle VAs, fascicular VAs, and mitral annular

150 syndrome is characterized by fascicular and papillary muscle VE that triggers ventricular fibrillati

151 er in 6 of 6 cardiac arrest patients (4 from papillary muscle) and Purkinje origin of dominant VE was

152 in of dominant VE was seen in 5 of 8 (3 from papillary muscle) nonarrest patients.

153 ead morphology, can help distinguish between papillary muscle, fascicular, and mitral annular VAs.

154 Patients undergoing catheter ablation for papillary muscle, fascicular, or mitral annular VAs were

155 Contracting isolated papillary muscles and cardiomyocytes from controls and m

156 s, with a wide array of malformations of the papillary muscles and chordae, that can be detected by t

157 Fibrosis of the papillary muscles and inferobasal left ventricular wall,

158 aflets and left ventricular (LV) fibrosis of papillary muscles and inferobasal wall.

159 ong the muscle fibers or in fiber tension in papillary muscles from heterozygous global Vcl null mice

160 mias (VAs) arising from the left ventricle's papillary muscles has been associated with inconsistent

161 is was detected at histology at the level of papillary muscles in all patients, and inferobasal wall

162 arction (MI), leaflet tethering by displaced papillary muscles induces mitral regurgitation (MR), whi

163 ications of catheter ablation of VA from the papillary muscles of the left ventricle with either cryo

164 erolateral papillary muscle or posteromedial papillary muscles of the left ventricle.

165 s force and [Ca(2+)]i measurements on intact papillary muscles show that enhancement of relaxation in

166 orce and [Ca(2+)]in measurements in isolated papillary muscles showed that the increased force and tw

167 illow height (P<0.0001), longer lengths from papillary muscles to coaptation (P<0.0001), and more fre

168 cTnC for the thin filament in reconstituted papillary muscles to provide evidence of an allosteric m

169 The contractility of cardiac papillary muscles was also restored in CRISPR-edited car

170 RV trabeculations and papillary muscles were considered cavity volume.

171 Left ventricular papillary muscles were excised from aortic-banded or sha

172 quence similar to sinus rhythm or arose near papillary muscles, and (2) stable pattern, in which acti

173 impairment of lateral shortening between the papillary muscles, and not passive ventricular size, tha

174 chanical stretch of the inferobasal wall and papillary muscles, eventually leading to myocardial hype

175 uctural heart disease can originate from the papillary muscles, fascicles, and mitral annulus.

176 ithin the body and to study the integrity of papillary muscles, the fibrous tissue of cardiac valve a

177 ng histologic subtypes: chromophobe (n = 5), papillary (n = 5), and medullary (n = 2) RCC and unclass

178 hromatid cohesion and segregation, in 36% of papillary non-invasive urothelial carcinomas and 16% of

179 All patients had at least 1 left ventricular papillary or fascicular VE focus.

180 redominant histologic pattern-lepidic (LEP), papillary (PAP), acinar (ACN), micropapillary (MIP), or

181 ulate the genomic alterations found in human papillary (pRCC) and clear cell RCC (ccRCC), the most co

182 nal cell carcinomas (nccRCCs), consisting of papillary (pRCC), chromophobe (chRCC) and translocation

183 known as kidney renal clear cell carcinoma), papillary (pRCC, also known as kidney papillary) and chr

184 s include thick, irregular walls and septae; papillary projections and solid, echogenic foci.

185 pt segment that expressed TFF2 and overlying papillary projections.

186 oth kidneys showed multifocal TSC-associated papillary RCC (PRCC).

187 c and screening biomarkers for clear cell or papillary RCC and in the differential diagnosis of image

188 xia also enhances HGF-driven invasiveness by papillary RCC cells, but in the absence of VHL, loss sig

189 nd hypoxia invasive synergy in VHL-competent papillary RCC cells, illustrate the plasticity of invasi

190 r both clear cell (tau = 0.85; P < .001) and papillary RCC renal cell carcinoma (tau = 0.53; P < .001

191 e used to distinguish between clear cell and papillary RCC renal cell carcinoma , and it provides ins

192 shold to discriminate between clear cell and papillary RCC renal cell carcinoma , and it yielded the

193 ld for discriminating between clear cell and papillary RCC renal cell carcinoma , and results were va

194 omen) with diagnosis of either clear cell or papillary RCC renal cell carcinoma at pathologic analysi

195 discriminate clear cell RCC from oncocytoma, papillary RCC, and chromophobe RCC with accuracies of 77

196 imination of clear cell RCC from oncocytoma, papillary RCC, and chromophobe RCC.

197 4, 100) for detecting malignancy, most often papillary RCC.

198 xhibited the highest miR-126 expression, and papillary RCCs exhibited the lowest expression.

199 Eighteen of 20 papillary RCCs were hypovascular.

200 A total of 170 clear cell RCCs, 57 papillary RCCs, 49 oncocytomas, and 22 chromophobe RCCs

201 ation of clear cell RCC from chromophobe and papillary RCCs.

202 o severe upper and lower tarsal conjunctival papillary reaction, without corneal or eyelid changes an

203 ggressive form of collecting duct and type 2 papillary renal cancer.

204 enal intraepithelial neoplasia, and invasive papillary renal carcinoma.

205 Purpose Patients with advanced papillary renal cell carcinoma (PRCC) have limited thera

206 Papillary renal cell carcinoma (pRCC) is an important su

207 in MET have been described in patients with papillary renal cell carcinoma (PRCC).

208 In hereditary type 2 papillary renal cell carcinoma (PRCC2, also known as her

209 omarkers to diagnose malignant clear cell or papillary renal cell carcinoma (RCC) in a screening para

210 The histomorphological subtyping of papillary renal cell carcinomas (pRCCs) has improved the

211 Furthermore, type 2 papillary renal-cell carcinoma consisted of at least thr

212 is known about the genetic basis of sporadic papillary renal-cell carcinoma, and no effective forms o

213 Papillary renal-cell carcinoma, which accounts for 15 to

214 as observed in a distinct subgroup of type 2 papillary renal-cell carcinomas that was characterized b

215 Type 1 and type 2 papillary renal-cell carcinomas were shown to be clinica

216 Type 1 and type 2 papillary renal-cell carcinomas were shown to be differe

217 ve molecular characterization of 161 primary papillary renal-cell carcinomas, using whole-exome seque

218 e 22-80 years]) were treated for symptomatic papillary retinal hemangioma.

219 ed in high-grade primary tumor patients with papillary serous tumors of the ovary.

220 ORR was higher in patients with significant papillary (seven of 18) or chromophobe (two of five) ele

221 hese results extend previous observations of papillary stem cell activity and collecting duct plastic

222 ologies (including benign biliary stricture, papillary stenosis, choledocholithiasis, extrinsic compr

223 -) and KC/Tff2(-/-) mice developed prominent papillary structures in the duct epithelium with cystic

224 e status, </= 1 in > 99% of patients; serous papillary subtype, 81.5%; stage III, 85.9%; and cancer a

225 that can distinguish between clear cell and papillary subtypes.

226 010-2013), primarily related to increases in papillary thyroid cancer (annual percent change, 4.4% [9

227 mutated gene in malignant melanoma (MM) and papillary thyroid cancer (PTC) and is causally involved

228 shown to be highly associated with increased papillary thyroid cancer (PTC) risk with an odds ratio o

229 Papillary thyroid cancer (PTC) was diagnosed in 97% of p

230 lysed a multi-generation CS-like family with papillary thyroid cancer (PTC), applying a combined link

231 BRAF V600E is a prominent oncogene in papillary thyroid cancer (PTC), but its role in PTC-rela

232 ty risk factor in the risk stratification of papillary thyroid cancer (PTC), but whether this is gene

233 nsidered to play a unique prognostic role in papillary thyroid cancer (PTC), with a distinct staging

234 E and TERT promoter mutations can coexist in papillary thyroid cancer (PTC).

235 ells (MSCs) in non-carcinogenic thyroids and papillary thyroid cancer (PTC).

236 E and TERT promoter mutations can coexist in papillary thyroid cancer (PTC).

237 on of a murine model of Braf(V600E) -induced papillary thyroid cancer (PTC).

238 only in patients age 45 years or older with papillary thyroid cancer (PTC); patients younger than ag

239 's thyroiditis is frequently associated with papillary thyroid cancer and may indeed be a risk factor

240 l disease risk in patients after surgery for papillary thyroid cancer as a function of primary tumor

241 unclear whether the increasing incidence of papillary thyroid cancer has been related to thyroid can

242 B-type RAF kinase mutations in papillary thyroid cancer have been found to be associate

243 About half of patients with papillary thyroid cancer have tumours with activating BR

244 in three patients with BRAF(V600E)-positive papillary thyroid cancer in a phase 1 trial.

245 Papillary thyroid cancer incidence increased for all SEE

246 ologically confirmed recurrent or metastatic papillary thyroid cancer refractory to radioactive iodin

247 ients with progressive, BRAF(V600E)-positive papillary thyroid cancer refractory to radioactive iodin

248 ent, and a long noncoding RNA (lncRNA) gene, papillary thyroid cancer susceptibility candidate 2 (PTC

249 sence of MSCs with a fibrotic fingerprint in papillary thyroid cancer tumors and the autocrine-paracr

250 iagnosed with thyroid cancer from 1974-2013, papillary thyroid cancer was the most common histologic

251 t patients diagnosed with localized >/= 1-cm papillary thyroid cancer who underwent thyroidectomy wit

252 Patients who undergo surgery for papillary thyroid cancer with only a limited lymph node

253 eptor kinase that undergoes rearrangement in papillary thyroid cancer).

254 urgeons and pathologists in the treatment of papillary thyroid cancer, and especially intermediate-ri

255 hyroiditis report an increased prevalence of papillary thyroid cancer, with a favorable disease profi

256 overshadowed by its more common counterpart-papillary thyroid cancer-despite its unique biological b

257 Papillary thyroid cancer-specific mortality for cases wi

258 Papillary thyroid cancer-specific mortality occurred in

259 Results: Papillary thyroid cancer-specific mortality occurred in

260 ve of disease-free survival in patients with papillary thyroid cancer.

261 The most frequent association is noted with papillary thyroid cancer.

262 od markedly increases the risk of developing papillary thyroid cancer.

263 r (95% CI, 1.1%-4.7%) for SEER distant stage papillary thyroid cancer.

264 st 4 decades, driven largely by increases in papillary thyroid cancer.

265 oid cancer mortality rate for advanced-stage papillary thyroid cancer.

266 afenib in patients with BRAF(V600E)-positive papillary thyroid cancer.

267 ten (Braf(V600E)/Pten(-/-)/TPO-Cre) leads to papillary thyroid cancers (PTC) that rapidly progress to

268 he Cancer Genome Atlas study (TCGA study) of papillary thyroid cancers (PTC).

269 E) mutation is found in approximately 40% of papillary thyroid cancers (PTC).

270 A substantial increase in papillary thyroid carcinoma (PTC) among children exposed

271 ological examination of the mass confirmed a papillary thyroid carcinoma (PTC) and enlarged metastati

272 Papillary thyroid carcinoma (PTC) displays strong but so

273 Papillary thyroid carcinoma (PTC) is the most common typ

274 Papillary thyroid carcinoma (PTC) remained to be the mos

275 Papillary thyroid carcinoma (PTC), the most frequent thy

276 rticularly those associated with a precursor papillary thyroid carcinoma (PTC).

277 NP (rs965513) firmly associated with risk of papillary thyroid carcinoma (PTC).

278 region shared by FOXE1 and PTCSC2 in a human papillary thyroid carcinoma cell line (KTC-1) and unaffe

279 ransforming growth factor-beta1 (TGF-beta1), papillary thyroid carcinoma cells acquired increased can

280 n, and that PRRX1 plays an important role in papillary thyroid carcinoma EMT and disease progression.

281 d a remarkable increase in radiation-induced papillary thyroid carcinoma in children and young adults

282 thyroidectomy caused by local recurrence of papillary thyroid carcinoma is extremely rare.

283 Papillary thyroid carcinoma overexpress transforming gro

284 is the most common endocrine malignancy, and papillary thyroid carcinoma represents the most common t

285 We conclude that papillary thyroid carcinoma tumor cells exhibit increase

286 We report a case of papillary thyroid carcinoma which invades IJV with hyper

287 osomal rearrangements found in radio-induced papillary thyroid carcinoma.

288 thrombosis is an extremely rare condition in papillary thyroid carcinoma.

289 sequencing and expression analysis of eight papillary thyroid carcinomas (PTC) to comprehensively ch

290 he number of genetic alterations detected in papillary thyroid carcinomas (PTC).

291 Papillary thyroid carcinomas that invade locally or meta

292 Management of papillary thyroid microcarcinomas should take into accou

293 able to the identification of intrathyroidal papillary thyroid microcarcinomas.

294 t ureteral orifice positive for a high-grade papillary transitional cell carcinoma (TCC) with muscula

295 cinoma in situ) or recurrence-free rate (for papillary tumors) of at least 50% at 6 months, 30% at 12

296 f confusion and malaise after resection of a papillary urothelial cancer.

297 or 3 (FGFR3) occur in up to 80% of low-grade papillary urothelial carcinoma of the bladder (LGP-UCB)

298 0T converted carcinoma-in-situ to high-grade papillary urothelial carcinoma.

299 showed a typical honeycomb pattern and round papillary vessels.

300 icropapillary or solid v lepidic, acinar, or papillary) was a significant prognostic factor in overal